IL-28 (interleukin 28), or IFNL2 (interferon λ2), belongs to the novel IFN type III family, which contains IL-29 and IL-28A and IL-28B. IL-28A and IL-28B share >95% sequence identity. This gene is localized to human chromosome 19.
Recombinant human IL-28A produced in Escherichia coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 19.6kDa.
IL-28A (interleukin 28) can inhibit multiple types of virus, and is also capable of preventing HSV-1 (herpes simplex virus type 1) infection of human neuronal cells. The antiviral property of IL-28A is attributable to IL-28A being capable of activating the expression of various Toll-like receptors (TLRs) and stimulating the TLR-mediated antiviral pathway, such as IFN regulatory factor 7, IFN-α, and the central IFN-α stimulated antiviral genes. IL-28A also acts as an inhibitory factor in HCV (hepatitis C virus) replication, and its expression is increased in HCV patients. This HCV antiviral activity is the result of IL-28A activating JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling pathway and the activation of certain interferon-stimulated genes (ISGs), such as 6-16 and 1-8U. Therefore, it might have potential as a therapeutic target in the treatment of HCV.
Lyophilized without additives.
Reconstitute in sterile dH2O not less than 100 μg/ml. This solution can then be diluted into other aqueous buffers.
Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.